Cano Garcia, Cristina http://orcid.org/0000-0002-4829-0241
Piccinelli, Mattia Luca
Tappero, Stefano
Panunzio, Andrea
Barletta, Francesco
Incesu, Reha-Baris
Tian, Zhe
Saad, Fred
Briganti, Alberto
Terrone, Carlo
Shariat, Shahrokh F.
Graefen, Markus
Tilki, Derya
Antonelli, Alessandro
De Cobelli, Ottavio
Kosiba, Marina
Banek, Severine
Kluth, Luis A.
Chun, Felix K. H.
Karakiewicz, Pierre I.
Article History
Received: 5 January 2023
Accepted: 11 February 2023
First Online: 23 February 2023
Declarations
:
: Shahrokh F. Shariat: Horonraria: Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, lpsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, Urogen. Consulting or Advisory Role: Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, lpsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, Urogen. Speakers’ Bureau: Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, lpsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, Urogen, Movember Foundation. Patents: Method to determine prognosis after therapy for prostate cancer—granted 2002–09-06, Methods to determine prognosis after therapy for bladder cancer—granted 2003–06-19, Prognostic methods for patients with prostatic disease—granted 2004–08-05; Soluble Fas urinary marker for the detection of bladder transitional cell carcinoma—granted 2010–07-20. Our research was conducted without any other potential conflicts of interest.
: All analyses and their reporting followed the SEER reporting guidelines. Due to the anonymously coded design of the SEER database, study‐specific Institutional Review Board ethics approval was not required.